BIOG-B.ST
BIOG-B.ST
SE0017769995
BioGaia AB ser. B
Loading chart...

Company Profile

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment offers packaging solutions. It sells its products through distribution partners or through its own distribution channels. The company was incorporated in 1990 and is headquartered in Stockholm, Sweden.

Related stocks

FAGR.BR
FAGR.BR • Belgium
FAGRON
22.2 EUR
1.83B USD 1Y +10.1%
PHN.MI
PHN.MI • Italy
PHARMANUTRA
71.1 EUR
762.88M USD 1Y +42.7%
ALVO
ALVO • Luxembourg
Alvotech
5.78 USD
2.06B USD 1Y -34.7%
ALM.MC
ALM.MC • Spain
ALMIRALL S.A.
10.08 EUR
2.46B USD 1Y -15.5%
ROVI.MC
ROVI.MC • Spain
LABORATORIOS FARMACEUTICOS ROVI
58.05 EUR
3.33B USD 1Y -1.1%
PRGO
PRGO • Ireland
Perrigo Company plc
15.06 USD
2.09B USD 1Y -33%
PPGN.SW
PPGN.SW • Switzerland
POLYPEPTIDE N
43.85 CHF
1.74B USD 1Y +68.2%
DMP.DE
DMP.DE • Germany
Dermapharm Holding SE I
38.4 EUR
2.13B USD 1Y +15.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
32.3% p.a.
Max Drawdown (5Y)
-41.1%
Sharpe Ratio (5Y)
0.11
Beta Factor
0.27
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (32.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -41.1% in the extended horizon.
ende